Abstract: This disclosure describes compounds of Formula (I), stereoisomers, side compounds thereof, pharmaceutical compositions and methods of manufacturing such compounds, using silylation reagents and producing compositions and products made using such methods. More particularly, this disclosure describes manufacture of trofinetide and side products, compositions and products containing such compounds, for pharmaceutical uses to treat neurodegenerative or neurodevelopmental disorders.

Abstract: This disclosure describes compounds of Formula (I), stereoisomers, side compounds thereof, pharmaceutical compositions and methods of manufacturing such compounds, using silylation reagents and producing compositions and products made using such methods. More particularly, this disclosure describes manufacture of trofinetide and side products, compositions and products containing such compounds, for pharmaceutical uses to treat neurodegenerative or neurodevelopmental disorders.

Abstract: This disclosure describes compounds of Formula (I), stereoisomers, side compounds thereof, pharmaceutical compositions and methods of manufacturing such compounds, using silylation reagents and producing compositions and products made using such methods. More particularly, this disclosure describes manufacture of trofinetide and side products, compositions and products containing such compounds, for pharmaceutical uses to treat neurodegenerative or neurodevelopmental disorders.

Abstract: This disclosure describes compounds of Formula (I), stereoisomers, side compounds thereof, pharmaceutical compositions and methods of manufacturing such compounds, using silylation reagents and producing compositions and products made using such methods. More particularly, this disclosure describes manufacture of trofinetide and side products, compositions and products containing such compounds, for pharmaceutical uses to treat neurodegenerative or neurodevelopmental disorders.

Abstract: This disclosure describes compounds of Formula (I), stereoisomers, side compounds thereof, pharmaceutical compositions and methods of manufacturing such compounds, using silylation reagents and producing compositions and products made using such methods. More particularly, this disclosure describes manufacture of trofinetide and side products, compositions and products containing such compounds, for pharmaceutical uses to treat neurodegenerative or neurodevelopmental disorders.

Abstract: Disclosed is a metal complex having a partial structure represented by the following Formula (I-0) or a tautomer thereof: formula (I-0) Cy is a 5 to 7 membered heterocyclic ring, preferably a 6-membered ring, which may be aromatic, non aromatic or partially aromatic and which coordinates to the metal atom through a carbon atom; A is a nitrogen atom a is an integer equal or superior to 1; D is an electron donor group; and b is an integer equal or superior to 1.

Abstract: Light emitting materials comprising multinuclear metal complexes comprising at least two metal atoms and a metal bridging ligand bound to said at least two metal atoms. It relates more particularly to a multinuclear complex of Formula (I): {-[L]2M-B-}n, wherein L is a bidentate ligand; M represents a transition metal having an atomic number of at least 40, and each M can be the same or different at each occurrence; B is a 2-connecting short metal bridging ligand bound to said at least two metal atoms, where the metal bridging ligand comprises coordinating atoms independently selected from the group consisting of nitrogen, phosphorous, carbon, oxygen, sulphur and selenium in 1,2 or 1,3 mutual position. (1,2-? or 1,3-? bonding mode); and n is an integer larger than 1.

Abstract: Disclosed is a metal complex having a partial structure represented by the following Formula (I-0) or a tautomer thereof: formula (I-0) Cy is a 5 to 7 membered heterocyclic ring, preferably a 6-membered ring, which may be aromatic, non aromatic or partially aromatic and which coordinates to the metal atom through a carbon atom; A is a nitrogen atom a is an integer equal or superior to 1; D is an electron donor group; and b is an integer equal or superior to 1.

Abstract: The present invention relates to an organometallic complex, to the preparation of said material, to the use of said material and to a light emitting device which transform electric energy into light. The present invention is further related to provide phosphorescent complexes which contribute to extend the life time in operation of said OLEDs and especially when they are involved in the EL. The objectives of this invention are accomplished by iridium complex comprising 7-membered fused ring ligands which are tris-homoleptic or bis-homoleptic with an ancillary ligand.

Abstract: The present invention relates to light emitting materials comprising novel ortho-metalated transition metal complexes [C^N]2M[N^N] comprising two orthometalated ligands (C^N ligands) and a neutral bidentate bipyridine ligand (N^N). Surprisingly, it has been found that when the metal binds both orthometalated chelate C^N ligands and a neutral bidentate bipyridine ligand (N^N), these ligands participate in the emission process, thus greatly improving the red emission efficiency of complexes [C^N]2M[N^N]. The present invention further relates to the use of such light emitting materials and an organic light emitting device comprising such light emitting material.

Abstract: White light emitting material comprising a complex salt of the general formula [M1m+]x [M2n?]y wherein: x m=y n, [M13+] and [M2n?] are ionic light emitting moieties which have complementary emission spectra, one emitting in the blue region of the visible spectra and the other, in the red region of the visible spectra, and wherein at least one of M1 and M2 is a metallic complex.

Abstract: A light emitting material comprising a complex of formula (I): (L1)x-M-(L2)y wherein L1 is a mono-anionic bidentate carbon-coordinating ligand comprising the structural element (II) in a ring system, wherein R1 is a substituent selected from the group consisting of R1-1 to R1-8, the use thereof as emissive materials in organic light emitting devices, and organic light emitting devices comprising said emissive material.

Abstract: The present invention relates to light emitting materials including a novel Ir complex, where the Ir is provided with a primary ligand selected from phenyl pyridine ligands substituted with at least one Cl atom. Such light emitting materials have been found to have a significantly enhanced photoluminescence quantum yield over other Ir complexes with a phenyl pyridine ligand having no Cl atom, or even over those with a phenyl pyridine ligand having a halogen atom other than Cl, such as a Br or F atom, and as a result specifically improve the efficiency of a light emitting device. The present invention further relates to the use of such light emitting materials and an organic light emitting device including such light emitting materials.

Abstract: Light emitting materials comprising multinuclear metal complexes comprising at least two metal atoms and a metal bridging ligand bound to said at least two metal atoms. It relates more particularly to a multinuclear complex of Formula (I): {-[L]2M-B-}n, wherein L is a bidentate ligand; M represents a transition metal having an atomic number of at least 40, and each M can be the same or different at each occurrence; B is a 2-connecting short metal bridging ligand bound to said at least two metal atoms, where the metal bridging ligand comprises coordinating atoms independently selected from the group consisting of nitrogen, phosphorous, carbon, oxygen, sulphur and selenium in 1,2 or 1,3 mutual position.(1,2-? or 1,3-? bonding mode); and n is an integer larger than 1.

Abstract: The present invention relates to light emitting materials comprising novel ortho-metalated transition metal complexes [C?N]2M[N?N] comprising two orthometalated ligands (C?N ligands) and a neutral bidentate bipyridine ligand (N?N). Surprisingly, it has been found that when the metal binds both orthometalated chelate C?N ligands and a neutral bidentate bipyridine ligand (N?N), these ligands participate in the emission process, thus greatly improving the red emission efficiency of complexes [C?N]2M[N?N]. The present invention further relates to the use of such light emitting materials and an organic light emitting device comprising such light emitting material.

Abstract: A system for injecting an air/fuel mixture into a combustion chamber of a turbomachine, the system having an injector comprising: an axial internal volume opening out at one end via an axial outlet for the air/fuel mixture; a first fuel feed stage having a plurality of first fuel feed orifices which open out into the internal volume, which are distributed around an axis of the injector, and which are connected by fuel feed channels to an inlet for admitting fuel into the injector; and at least one air feed channel which opens out into the internal volume and which is connected to an inlet for admitting air into the injector. The injector further comprises at least one second fuel feed stage with a plurality of second fuel feed orifices which open out into the internal volume, which are distributed around the axis of the injector, and which are connected to said inlet for admitting fuel into the injector via fuel feed channels which coincide at least in part with the fuel feed channels of said first stage.

Abstract: A system for injecting an air/fuel mixture into a combustion chamber of a turbomachine, the system having an injector comprising: an axial internal volume opening out at one end via an axial outlet for the air/fuel mixture; a first fuel feed stage having a plurality of first fuel feed orifices which open out into the internal volume, which are distributed around an axis of the injector, and which are connected by fuel feed channels to an inlet for admitting fuel into the injector; and at least one air feed channel which opens out into the internal volume and which is connected to an inlet for admitting air into the injector. The injector further comprises at least one second fuel feed stage with a plurality of second fuel feed orifices which open out into the internal volume, which are distributed around the axis of the injector, and which are connected to said inlet for admitting fuel into the injector via fuel feed channels which coincide at least in part with the fuel feed channels of said first stage.

Abstract: A combustion chamber for a gas turbine made up of outer and inner side walls, the combustion chamber being received in a casing so as to define an annular space between the combustion chamber and the casing in which there flows air for combustion, for dilution, and for cooling the combustion chamber, the side walls of the combustion chamber being pierced by a plurality of holes in which bushings of substantially elliptical right section are fixed to define air injection passages for injecting air into the combustion chamber, each bushing having a peripheral wall in which at least one additional orifice is formed opening out into the combustion chamber in the immediate vicinity of the side wall of the combustion chamber in which said bushing is fixed so that the air passing through said orifice flows substantially along said peripheral wall, the peripheral wall of each bushing having at least one groove opening out into the annular space and into which the or each orifice opens out so as to be fed with air and